This study presents a novel supramolecular assembly strategy for site-specific conjugation of antibody-drug conjugates (ADCs), significantly improving conjugation homogeneity and stability, offering a modular and scalable new tool for preclinical design in tumor-targeted therapy.
Literature Overview
The paper titled 'Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering,' published in Nature Communications, systematically explores the use of supramolecular coiled-coil structures for site-specific modification of antibody-drug conjugates (ADCs). The authors developed a non-covalent assembly platform based on heterodimeric coiled-coils, enabling modular conjugation of antibodies with diverse payloads (e.g., cytotoxins, polymers, enzymes, fluorescent probes) under mild aqueous conditions, while preserving the antibody’s antigen-binding capacity and Fc functionality. This method involves genetic fusion of a receptor peptide to the antibody’s C-terminus, followed by self-assembly with a payload-carrying docking peptide, achieving high homogeneity in conjugation. Compared to conventional lysine or cysteine conjugation techniques, this strategy overcomes limitations such as high heterogeneity and uncontrolled conjugation sites.Background Knowledge
Currently, antibody-drug conjugates (ADCs) show great promise in cancer therapy, but their clinical translation is limited by the non-specificity of conjugation processes, leading to uneven drug-to-antibody ratios (DAR), unstable pharmacokinetics, and off-target toxicity. Traditional methods rely on lysine residues or hinge-region cysteines of IgG for conjugation, but the abundance of these sites results in highly heterogeneous products. Additionally, the thioether bonds formed in cysteine-based conjugates are prone to deconjugation in vivo, compromising therapeutic efficacy. Therefore, developing novel technologies that enable precise control over conjugation sites and DAR has become a major focus in the field. This study addresses the issues of conjugation homogeneity and stability in HER2-targeted ADCs by introducing a coiled-coil-based supramolecular recognition system, offering a new pathway for next-generation ADC design. The strategy was validated in a tumor model with high ErbB2 expression, demonstrating superior antitumor activity compared to conventional ADCs.
Research Methods and Experiments
The authors genetically fused coiled-coil receptor peptides (P1–P4) to the C-terminus of the heavy chain of trastuzumab and expressed and purified the antibody in Expi293F cells. Structural integrity and monomeric state were verified using circular dichroism (CD) and size-exclusion chromatography (SEC). Docking peptides modified with azide groups (e.g., P4N3) were synthesized and conjugated to various payloads—including MMAE, DM1, PEG, fluorescent dyes, DNA oligonucleotides, and enzymes (e.g., HRP)—via DBCO-azide click chemistry. The conjugated products were incubated with the antibody-bound receptor peptides in PBS at 37°C for one hour to allow self-assembly, followed by purification via centrifugal filtration. The functionality and binding affinity of the resulting conjugates were systematically evaluated using ELISA, flow cytometry, MTS cytotoxicity assays, and bio-layer interferometry (BLI).
In vivo, the authors established a SKOV-3 (ErbB2-high) human ovarian cancer peritoneal xenograft model to assess the pharmacokinetics, biodistribution, and antitumor efficacy of the ADCs. Payload distribution was monitored via IVIS imaging, intact conjugate levels were measured by ELISA, and therapeutic outcomes were evaluated based on tumor volume and weight, with head-to-head comparisons against commercial ADCs (e.g., trastuzumab vedotin). Additionally, a dual-payload system was designed using tandem receptor peptides to enable site-specific conjugation of two distinct payloads, demonstrating the platform’s versatility.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents the first universal conjugation platform for ADCs based on supramolecular self-assembly, overcoming the limitations of traditional covalent conjugation. Its modular design allows rapid screening of various payload-antibody combinations, greatly accelerating drug discovery. More importantly, its high stability and homogeneity are expected to reduce toxicity and immunogenicity in clinical ADCs, thereby improving the therapeutic index.
Future applications of this technology may extend to other targets such as Trop2 and Nectin-4 for next-generation ADC development. When combined with gene knock-in mouse models, it can be used to evaluate immunogenicity in humanized immune systems. Furthermore, the dual-payload system could enable conjugation of bispecific immunomodulators, facilitating synergistic activation of antitumor immunity and advancing the development of immune-conjugate therapeutics.
Conclusion
The supramolecular coiled-coil peptide platform developed in this study offers a revolutionary solution for site-specific modification of antibody-drug conjugates. Through a non-covalent self-assembly mechanism, it achieves high homogeneity, stability, and modularity in conjugation, overcoming the challenges of heterogeneity and instability inherent in conventional ADCs. In HER2-positive ovarian cancer models, this ADC demonstrates exceptional antitumor activity, rivaling or surpassing existing clinical ADCs, and exhibits strong translational potential. Beyond tumor-targeted therapy, this technology can be extended to bispecific conjugation, immunomodulatory drug delivery, and diagnostic probe development, serving as a universal tool for precision medicine. In the future, integration with humanized mouse models and pharmacokinetic studies may accelerate its clinical translation, establishing it as a core technological platform for next-generation ADCs and reshaping the treatment landscape for ErbB2-driven cancers.
